MABN794 Sigma-AldrichAnti-GLAST Antibody, clone 8C11.1
Anti-GLAST Antibody, clone 8C11.1 is an antibody against GLAST for use in Western Blotting, Immunohistochemistry .
More>> Anti-GLAST Antibody, clone 8C11.1 is an antibody against GLAST for use in Western Blotting, Immunohistochemistry . Less<<Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, R | WB, IH(P) | M | Purified | Monoclonal Antibody |
| References |
|---|
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified mouse monoclonal IgG1λ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. |
| Quality Level | MQ100 |
| Physicochemical Information |
|---|
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 100 μg |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| MABN794 | 04055977166644 |
Documentation
Anti-GLAST Antibody, clone 8C11.1 SDS
| Title |
|---|
Anti-GLAST Antibody, clone 8C11.1 Certificates of Analysis
| Title | Lot Number |
|---|---|
| Anti-GLAST, clone 8C11.1 - 3167609 | 3167609 |
| Anti-GLAST, clone 8C11.1 - 3250991 | 3250991 |
| Anti-GLAST, clone 8C11.1 - 3389915 | 3389915 |
| Anti-GLAST, clone 8C11.1 - 3866884 | 3866884 |
| Anti-GLAST, clone 8C11.1 - 3944522 | 3944522 |
| Anti-GLAST, clone 8C11.1 - 4163455 | 4163455 |
| Anti-GLAST, clone 8C11.1 - 4216321 | 4216321 |
| Anti-GLAST, clone 8C11.1 -2710635 | 2710635 |
| Anti-GLAST, clone 8C11.1 -2764892 | 2764892 |
| Anti-GLAST, clone 8C11.1 -2814887 | 2814887 |
Technical Info
| Title |
|---|
| White Paper: Further considerations of antibody validation and usage. |



